23 Oct 2013, BioSpectrum Bureau , BioSpectrum
Mumbai: Univar, a leading global chemical distributor, announced today that it has entered into an agreement with India-based Swati Spentose to become its exclusive distributor of Lidocaine products, including Lidocaine Base and Lidocaine HCl in the US.
The agreement with Swati Spentose includes distribution in the US and Puerto Rico for both Lidocaine Base and Lidocaine HCl. The products are used in a variety of anaesthetic and antiarrhythmic applications in the form of topical, oral, transdermal and injectable products.
Univar's offering to pharmaceutical manufacturers extends beyond traditional technical and formulation support. It includes detailed insight into the industry's market trends and complex regulatory demands, including stringent quality control and services such as change control management.
Mr Tom Nist, director, pharmaceutical ingredients, Univar, US, said that, "We are very excited to begin this relationship with Swati Spentose. The combined manufacturing expertise from Swati Spentose and Univar's marketing and sales capabilities offers customers greater access to these active pharmaceutical ingredients (API). The Lidocaine Base and Lidocaine HCl are excellent additions to Univar's API portfolio."
Ms Swati Jajodia, CEO, Swati Spentose, said that, "As part of our ongoing commitment to world class manufacturing, we are focused on partnering with companies across the value chain to provide the most comprehensive service to our customers. Univar's extensive distribution network and commitment to safety, makes it an excellent partner to help us reach more customers with our lidocaine products."